



Asse HPG








Sinergismo ormonale





GnRH


Pyro-Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-CO-NH2

10 aa

(Chr 8, 4 esoni)

Ipotalamo nucleo arcuato

Gonadi Placenta



Recettore 7DTM Gq PI DAG

Chr 14 diversi esoni

2 splicing alternativi (corta GnRHR1 fungerebbe da inibitore)

SNC


Ipofisi

Gonadi Ghiandole mammarie

Intestino

Tumori etc

Various molecular forms of inhibins and activins








Table 2. Effect of null mutations of TGF-β family members on gonadal development


Family member	Gender affected	Defect	Refs
TGF-β	?	Early death from inflammatory disease	9, 10
Inhibin	Both	Sex cord tumor	18
Activin BA	?	Early death from palatal defects	19
Activin BB	Female	Normal ovaries but litters die	20, 21
Activin RII	Female	No estrous cycles	20, 22
GDF-9	Female	Lack of follicular maturation	50
BMP-8A	Male	Spermatogenesis is not sustained, occasional epididymal degeneration	48
BMP-8B	Male	Defects in spermatogenesis initiation and maintenance	
AMH and AMHRII	Both	Female infertility owing to ovarian and Müllerian duct regression, Leydig cell hyperplasia and tumors	47, 65


Recettori

TGF-β Receptors I & II













Sinergismo GnRH-Act




Gonadotropine e recettori








Estrogeni



Pathways of Testosterone Action LH **Amplification Pathway** (prostate, skin) Androgen 5α-reductas receptor (5-10%)Testosterone Direct Pathway Androgen 5-7 mg/day receptor (muscle) Aromatase (0.1%)Estrogen Estradiol receptor Hepatic oxidation **Diversification Pathway** & conjugation Renal excretion (brain, bone) Inactivation Pathway



Recettore androgeni





Figure 2. Schematic diagram of the domain structure of the human androgen receptor, N-terminal, DNA-binding and androgen-binding domains, as well as the positions of oligo- and polyamino acid tracts are indicated. Different lengths of the polyglutamine tract have been linked to spinal and bulbar muscular atrophy and prostate cancer.

Chr X

Coattivatori










Recettori estrogeni

ERa Chr 6

ERb Chr 14






Table 1. Estrogen receptors (ERs) as novel targets for disease

Target tissue	Estrogen receptor present	Disease	
Uterus	ERα	Uterine cancer	
Prostate stroma	ERa	Benign prostatic hyperplasia	
Ovary theca cells	ERα	Polycystic ovary syndrome	
Bone	ERa	Osteoporosis	
Breast epithelium	ERa, ERB, ERBcx*	Breast cancer	
Breast stroma	ERB		
Brain	ERa, ERB	Stroke	
	SPORTSHIP	Hypertension	
		Obesity	
		Dementia	
Sympathetic ganglia	ERB	Hypertension	
		Bladder control	
Colon	ERB	Colon cancer	
Prostate epithelium	ERB, ERBCX*	Prostate cancer	
Ovarian granulosa cells	ERB	Infertility, polycystic ovarian s	
Dorsal raphe	ERB	Depression	
Bone marrow	ERB	Leukaemia	






Table 2. Differential actions of ERα and ERβ on different promoters and with different ligands*

Ligand	ER	Interaction site			
		ERE	AP-1 ^b	Sp1	NF-xB promoter
E2	ERα	1	1	† RARa1 promoter [24]; IGF-1 promoter [25]	1
	ERβ	1	NC	No change in RARα1 promoter; † IGF-1 promoter	NC
Tamoxifen	ERα	1	1	L RARa1 promoter	1
	ERB	1	1	† RARa1 promoter	NC


Variazione ormoni pubertà





Differenziamento gonadico




Diff gonadico








Gene	Locus	Herança*	Fenotipo Predominante
KAL	Xp22.3	X-linked	Hipogonadismo hipogonadotrófico e anosmia/hiposmia
FGFR1	8p11.2	AD	Hipogonadismo hipogonadotrófico e anosmia/hiposmia
SF1	9q33	ARorAD	Sexo reverso XY, agenesia gonadal associada ou não à insuficiência adrenal
DAX1	Xp21.3	Ligada ao X	Hipogonadismo e hipoplasia adrenal congênita; puber- dade precoce independente de gonadotrofinas em meninos
Leptina	7q31.3	AR	Hipogonadismo hipogonadotrófico e obesidade
PC1	5q15	AR	Hipogonadismo hipogonadotrófico, hipocortisolismo e obesidade
GnRH	8p21	ND	Provável hipogonadismo hipogonadotrófico isolado
GnRHR	4q21.2	AR	Hipogonadismo hipogonadotrófico isolado
HESX1	3p21.2	AR/AD	Hipopituitarismo, neurohipófise ectópica, displasia septo óptica
LHX3	9q34.3	AR	Hipopituitarismo, mai formações esqueléticas cervicais
PROP1	5q35	AR	Hipopituitarismo
FSHR	2p21	AR	Hipogonadismo hipergonadotrófico. Falência ovariana precoce
LHR	2p21	AR	Hipogonadismo hipergonadotrófico em ambos os sexos; genitália ambígua em homens
LHβ	19q13.32	AR	Hipogonadismo hipergonadotrófico
FSHβ	11p13	AR	Hipogonadismo hipergonadotrofico





Differenziamento aree cerebrale

Secrezione pulsatile GnRH ritmi circadiani

Amigdala più sviluppata


Centri ipotalamici area preottica aggressività +


Sistema limbico - corpo calloso - area del linguaggio -


Aree corticali.....aree prefrontali...


Il testosterone fetale passa la barriera ematoencefalica e viene trasformato in alcune aree in estrogeni.

Gli estrogeni placentari non passano la barriera ematoencefalica perché legati a proteine placentari ad alta affinità










5alfa reduttasi



Prostata, vescicole seminali, epididimo, cute SNC



5α**R**-1

DUTASTERIDE entrambe

